tbuckley/cabot-search huggingface dataset:
AB0800 Safety and clinical response to rituximab in patients with connective tissue disease-associated interstitial lung disease: Preliminary results
Authors: F.I. Romero, S. Recuero, J. Gόmez-Seco, M.J. Rodríguez-Nieto, T. Presa, I. Mahillo, C. Serrano, G. Herrero-Beaumont, O. Sánchez-Pernaute
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rituximab may benefit patients with connective tissue diseases (CTD). <h3>Objectives</h3> We present here short-term safety and clinical outcomes of rituximab in CTD-associated interstitial lung disease (ILD) in a real-life clinical setting. <h3>Methods</h3> All patients with CTD-associated ILD treated with rituximab in our ILD clinic were included. Efficacy was assessed by pulmonary function tests and high-resolution computed tomography (HRCT). Results are expressed as median (limits). ILD exacerbations and safety were assessed. <h3>Results</h3> A total of 14 patients with CTD-associated ILD (29% rheumatoid arthritis, 21% primary Sjögren syndrome, 21% unclassifiable CTD, 14% systemic sclerosis and 14% inflammatory myopathy) received a dose of 4000 (2000 – 6000) mg Rituximab over an observation period of 161 patient-year. The distribution of morphologic ILD patterns were: 57% usual interstitial pneumonia (UIP), 21% unclassifiable ILD, 7% nonspecific interstitial pneumonia (NSIP), 7% cryptogenic organizing pneumonia (COP) and 7% lymphoid interstitial pneumonia (LIP). At baseline, IgG levels and leukocyte subset counts were within normal range, with reduced numbers of unswitched memory B cells. Incidence infection rate during RTX therapy was 4.35/100 patient-month with only one case being severe. There was 1 death, due to neutropenia with a disseminated fungal infection. Longitudinal pulmonary function data available in 12 patients showed an overall improvement in FVC (85%±19 versus 73%±18) and DLCO (58%±18 versus 45%±19). Radiographic progression could be evaluated in 6 patients, with five showing lack of progression and one improvement. ILD incidence relapse rate during rituximab therapy was 0.745/100 patient-month compared to 5.56/100 patient-month during the pre-treatment period. <h3>Conclusions</h3> Our preliminary data indicate that rituximab is safe in the study population. Our patients had a notoriously low exacerbation rate. Although optimal outcome measures in the short term are difficult to establish, we could confirm disease stabilization in most patients. <h3>Disclosure of Interest</h3> None Declared
False-Negative Scintigraphy With Tc-99m Sestamibi in Stage IV Neuroblastoma
Authors: Z Ozcan, G Erenel, S Aksoylar, S Kansoy, Z Burak, H Ozkiliç
Journal: Clinical Nuclear Medicine (1999)

Tc-99m sestamibi, originally developed for myocardial studies, has been used as a tumor-seeking agent. Recently, the agent also was reported to be a functional tracer to predict multidrug resistance-related p-glycoprotein expression in tumor tissue. The current report presents the authors' experience with sestamibi tumor scintigraphy in a neuroblastoma. Although I-131 MIBG tumor imaging and Tc-99m MDP bone scanning accurately demonstrated the extent of the disease, Tc-99m sestamibi showed no accumulation in primary and metastatic foci. Lack of sestamibi uptake was initially thought to be suggestive of failure to respond to chemotherapy because of p-glycoprotein expression. However, the patient responded well to chemotherapy and complete remission was achieved. The failure of Tc-99m sestamibi to detect a neuroblastoma and the lack of sestamibi accumulation in the tumor may not always be related to chemotherapy resistance.
THU0340 Delta Neutrophil Index as a Useful Marker for the Differential Diagnosis between Flare and Infection in Febrile Patients with Systemic Lupus Erythematosus
Authors: J. Y. Pyo, J. S. Park, Y.-B. Park, S.-K. Lee, Y.-J. Ha, S.-W. Lee
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Differentiating systemic lupus erythematosus (SLE) flare from infection in febrile SLE patients is critical for deciding the treatment strategies. Since fever is the common symptom of systemic lupus erythematosus (SLE), it is uneasy to discriminate between SLE flare and infection. Delta neutrophil index (DNI) is a difference between leukocyte subfractions which corresponds to the fraction of immature granulocyte. Delta neutrophil index (DNI) was reported to be associated with infection and sepsis. <h3>Objectives</h3> This study is performed to elucidate the possible role of DNI as a predictive marker in differentiating between disease activity and infection. <h3>Methods</h3> A total of 92 febrile SLE patients with 111 episodes of admissions from January 2010 to February 2012 were retrospectively reviewed. Receiver operating characteristic (ROC) curve was used to identify the optimal cutoff value of DNI for differentiating SLE flare from infection. We used logistic regression to find independent variables for predicting infection among several clinical and laboratory markers. <h3>Results</h3> The infection group showed higher white blood cell and neutrophil counts and higher levels of CRP and procalcitonin than the SLE flare group. Patients in the SLE flare group had significantly lower DNI than those in both infection groups, with and without bacteremia(<i>p</i>&lt;0.001). In multivariate logistic regression analysis, only DNI was a significant independent factor for the presence of infection (OR 18.9). When we selected DNI value of 2.77% as the cutoff for infection, SLE patients with DNI ≥ 2.77% were found to have a higher risk for infection than those with DNI &lt; 2.77% (Relative risk 8.48). <h3>Conclusions</h3> The present study is the first report to evaluate DNI in febrile SLE patients, and investigates its usefulness as a novel serologic marker for differentiating SLE flare from infection. Our findings demonstrate that DNI measurement in febrile SLE patients is useful for predicting coexisting infectious episode and helpful in making decisions about the treatment. <h3>Disclosure of Interest</h3> None Declared
THE CLINICAL UTILITY OF 18F-FDG POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY SCAN VERSUS 99MTC-HMPAO WHITE BLOOD CELL SINGLE-PHOTON EMISSION COMPUTERIZED TOMOGRAPHY IN THE EXTRA-CARDIAC WORK-UP OF PATIENTS WITH DUKE DEFINITE INFECTIVE ENDOCARDITIS
Authors: Trine K. Lauridsen, Kasper Iversen, Nikolaj Ihlemann, Philip Hasbak, Annika Loft Jakobsen, Anne Kiil Berthelsen, Anders Dahl, Danijela Dejanovic, Elisabeth Albrecht-Beste, Jann Mortensen, Andreas Kjaer, Henning Bundgaard, Niels Eske Bruun
Journal: Journal of the American College of Cardiology (2016)
The Effect of Ozone on Inner-City Children with Asthma
Authors: KATHLEEN M. MORTIMER, IRA B. TAGER, DOUGLAS W. DOCKERY, LUCAS M. NEAS, SUSAN REDLINE
Journal: American Journal of Respiratory and Critical Care Medicine (2000)

Within a cohort of 846 inner-city asthmatic children aged 4 to 9 yr, we looked for subgroups that were more susceptible to the effects of summer ozone. Daily diaries were compared with ambient ozone levels to evaluate effect modification by demographic and environmental characteristics. Children born > 3 wk prematurely or weighing < 5.5 lb. had greater declines in morning % peak expiratory flow rate (PEFR) (1.8% versus 0.3% per 15 ppb ozone, p < 0.05) and a higher incidence of morning symptoms (odds ratio = 1.42 versus 1.09 per 15 ppb ozone, p < 0.05) than did children who had been full-term infants of normal birthweight. Among children who had been of low birthweight (LBW) or had been premature infants, greater declines were seen among those whose reported baseline medication category was "no medication" (3.2% decline) or "steroids" (2.7%) as opposed to beta agonists or xanthines (0.8%) or cromolyn without steroids (0.1%). Among the children who had been normal birthweight and full-term infants, the cromolyn without steroids group had the greatest declines in %PEFR (1.3%, versus < 0.5% in each of the other three groups). Nonatopic children also had greater responses to ozone. We conclude that among an asthmatic cohort, children who had had an LBW or a premature birth showed the greatest responses to ozone.
SELF-REPORTED LOWER EXTREMITY EDEMA IN THE ABSENCE OF HEART FAILURE IS AN INDEPENDENT RISK FACTOR FOR INCIDENT HEART FAILURE AMONG COMMUNITY-DWELLING OLDER ADULTS
Authors: Benjamin Aronow, Raya Kheirbek, Gregg Fonarow, Prakash Deedwania, Michael Zile, Ralph H. Johnson, Nawar Shara, Charity Morgan, Wilbert Aronow, Michel White, Richard M. Allman, Stefan D. Anker, Ross Fletcher, Ali Ahmed
Journal: Journal of the American College of Cardiology (2015)
Important Differences Between a Triage Pedigree and Risk Assessment
Authors: Joy Larsen Haidle
Journal: Journal of Clinical Oncology (2014)

TO THE EDITOR: We would like to compliment Lu et al on their work tackling the complicated topic of triaging for inherited cancer predisposition and setting baseline recommendations for family history collection. However, we would like to emphasize that collecting the family history of only firstand second-degree relatives may be appropriate for triage, but it is not sufficient for a full cancer risk assessment. The gold standard for cancer risk assessment is a threeto four-generation pedigree with collection of health information on first-, second-, and third-degree relatives. The recommendations made by Lu et al may help with identifying many families who would benefit from a referral for genetic counseling and potentially genetic testing. However, as with any triage mechanism, some families will be missed, the percentage of which is unknown. The triage guidelines in this article may have limitations for individuals with a paternal family history of breast cancer or families with limited family structure. Physicians who identify families with a concerning family history or rare tumors or patients concerned about risk may enhance the care of their patient by referring to a provider with expertise in genetics, such as a genetic counselor. One of the barriers reported to obtaining a family history in a busy oncology clinic was time. The genetic testing landscape is changing rapidly, which makes it a challenge for health care providers to stay abreast of the data. Genetic counselors are uniquely positioned to assist oncologists in the collection of appropriate family histories and risk assessment. A list of genetic counselors may be found at www.nsgc.org.
Serologically Defined HL-A Antigens and Long-Term Survival of Cadaver Kidney Transplants
Authors: Jean Dausset, Jacques Hors, Marc Busson, Hilliard Festenstein, Roderick T. D. Oliver, Andrew M. I. Paris, John A. Sachs
Journal: New England Journal of Medicine (1974)

Original Article from The New England Journal of Medicine — Serologically Defined HL-A Antigens and Long-Term Survival of Cadaver Kidney Transplants — A Joint Analysis of 918 Cases Performed by France-Transplant and the London Transplant Group
Abstract 3047: The PML isoform IV is a negative regulator of nuclear EGFR's transcriptional activity in lung cancer.
Authors: Hong-Yi Kuo, Yi-Chen Chen, Hsiang-Yi Chang, Jen-Chong Jeng, Erh-Hsuan Lin, Chih-Ming Pan, Mong-Lien Wang, Yu-Ting Chou, Hsiu-Ming Shih, Cheng-Wen Wu
Journal: Cancer Research (2013)

Abstract EGF receptor (EGFR) is a membrane-bound receptor tyrosine kinase which can transduce intracellular signals responsible for cell proliferation. It is frequently overexpressed and/or constitutively activated in non-small cell lung cancer (NSCLC) and thus is considered as a major cause of this disease. Recently, EGFR has been found in the nucleus where the nuclear EGFR (nEGFR) can function as a transcription factor activating the transcription of genes such as cyclin D1 gene (CCND1) which is essential for cell proliferation. Nevertheless, how nEGFR's transcriptional activity is regulated remains unclear. Promyelocytic leukemia protein (PML) is a tumor suppressor which is lost in various cancers including lung cancer. However, the role of PML in the suppression of lung cancer growth is still unclear. When we investigated the role of PML in the regulation of lung cancer cell growth, we found that PML isoform IV (PMLIV) preferentially represses the growth of lung cancer cells bearing constitutively active EGFR. Besides, when growing in the EGFR activating conditions, the growth of EGFR wild-type bearing A549 cells has been repressed by PMIV overexpression. We also found that PMLIV has protein-protein interactions with nEGFR and represses the transcription of nEGFR target genes. We showed that PMLIV is recruited by nEGFR to the target promoters and reduces the promoter histone acetylation level via HDAC1. Together, our results suggest that PMLIV interacts with nEGFR upon EGFR activation and represses the transcription of nEGFR target genes such as CCND1 and thus leading to inhibition of the lung cancer cell growth. Citation Format: Hong-Yi Kuo, Yi-Chen Chen, Hsiang-Yi Chang, Jen-Chong Jeng, Erh-Hsuan Lin, Chih-Ming Pan, Mong-Lien Wang, Yu-Ting Chou, Hsiu-Ming Shih, Cheng-Wen Wu. The PML isoform IV is a negative regulator of nuclear EGFR's transcriptional activity in lung cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3047. doi:10.1158/1538-7445.AM2013-3047
The Cardinal Manifestations of Bardet–Biedl Syndrome, a Form of Laurence–Moon–Biedl Syndrome
Authors: J S Green, P S Parfrey, J D Harnett, N R Farid, B C Cramer, G Johnson, O Heath, P J McManamon, E O'Leary, W Pryse-Phillips
Journal: New England Journal of Medicine (1989)

To determine the interfamilial and intrafamilial variation in the expression of the Bardet-Biedl syndrome (a form of Laurence-Moon-Biedl syndrome), we looked for the five recognized features of the disorder (retinal dystrophy, obesity, polydactyly, mental retardation, and hypogonadism), plus possible renal manifestations, in some or all of 32 patients with this disorder. All 28 patients examined had severe retinal dystrophy, but only 2 had typical retinitis pigmentosa. Polydactyly was present in 18 of 31 patients, but syndactyly, brachydactyly, or both were present in all. Obesity was present in all but 1 of 25 patients. Only 13 of 32 patients were considered mentally retarded. Scores on verbal subtests of intelligence were usually lower than scores on performance tasks. Seven of eight men had small testes and genitalia, which was not due to hypogonadotropism. All 12 women studied had menstrual irregularities, and 3 had low serum estrogen levels (1 of these had hypogonadotropism, and 2 had primary gonadal failure). The remaining women who were of reproductive age had endocrinologic evidence of reproductive dysfunction. Diabetes mellitus was present in 9 of 20 patients. Renal structural or functional abnormalities were universal (n = 21), and three patients had end-stage renal failure. We conclude that the characteristic features of Bardet-Biedl syndrome are severe retinal dystrophy, dysmorphic extremities, obesity, renal abnormalities, and (in male patients only) hypogenitalism. Mental retardation, polydactyly, and hypogonadism in female patients are not necessarily present.
Sideroblastic Anemia with Dermal Photosensitivity and Greatly Increased Erythrocyte Protoporphyrin
Authors: Gerald Rothstein, G. Richard Lee, G. E. Cartwright
Journal: New England Journal of Medicine (1969)

Sideroblastic anemia was found in an elderly man in association with dermal photosensitivity, a greatly increased erythrocyte free protoporphyrin content and reduced erythrocyte catalase activity. Markedly reduced heme synthetase activity was found in the patient's reticulocytes. Since the activity of mixtures of the patient's cells with cells from a patient with hemolytic anemia was greater than the sum of the components of the mixture, the patient may have lacked an essential cofactor. The clinical, hematologic and biochemical manifestations of disease in this case appear to be consequences of this defect.
Transjugular Intrahepatic Portosystemic Shunt
Authors: M A Sadler, R S Shapiro
Journal: New England Journal of Medicine (1994)

Figure 1. Transjugular Intrahepatic Portosystemic Shunt. This hepatic Doppler sonogram in a 55-year-old man with alcoholic cirrhosis and portal hypertension shows the successful placement of a transjugular intrahepatic portosystemic shunt. The procedure was performed because of refractory and debilitating ascites. The shunt shows characteristic echogenicity (solid arrows), along with an intense (blue) signal from the shunted blood. Ascites (open arrow) is present anterior to the liver. After the placement of the shunt, the patient's esophageal varices regressed and the ascites improved without further therapy, until the shunt became thrombosed eight months later. The patient is currently awaiting liver transplantation.
Abstract 2831: Ornithine decarboxylase polymorphisms and risk of colorectal adenoma
Authors: Elizabeth L. Barry, Leila A. Mott, Robert S. Sandler, Dennis J. Ahnen, John A. Baron
Journal: Cancer Research (2010)

Abstract Introduction: In a recent randomized trial the combination of difluoromethylornithine (DFMO) and the NSAID sulindac was remarkably effective in reducing the risk of colorectal adenoma recurrence. DFMO is a specific inhibitor of ornithine decarboxylase (ODC), which catalyzes the first step in polyamine synthesis. ODC and polyamines, which regulate cell growth and survival, have long been associated with colon carcinogenesis. In previous studies a SNP in the ODC promoter region was associated with risk of adenoma and response to aspirin treatment. The objective of this research was to perform a more comprehensive investigation of the association of adenoma risk with common genetic variation across the entire ODC gene, including potential upstream and downstream regulatory regions. Methods: We investigated the association between genetic variation in the ODC gene and risk of adenoma recurrence among a cohort of 920 participants in the Aspirin/Folate Polyp Prevention Study. Using the Sequenom platform, we genotyped 29 SNPs within a 23kb region. Generalized linear regression was used to compute relative risks (RRs) and 95% confidence intervals (95% CIs) adjusted for age and gender. Interactions terms were used to test whether ODC genotype modified the protective effect of aspirin treatment. Results: As gene frequencies for 26 of the 29 SNPs varied significantly by race/ethnicity, analyses were limited to whites only (86%). There were 7 SNPs associated with increased risk and 3 with decreased risk of adenoma recurrence (see table). In addition, at least three SNPs without any main effect modified the effect of aspirin treatment: rs1405948 (P for interaction=0.048), rs28362422 (P=0.043), and rs4669584 (P=0.050). Conclusion: Our findings suggest that common genetic variation throughout the ODC gene and adjacent regulatory regions influence risk of adenoma recurrence as well as efficacy of aspirin treatment.Association of ODC polymorphisms with adenoma riskSNPRR95% CIP-valueModelMAFLocationrs23575511.231.06-1.440.008dominant0.345′ flankingrs23026141.371.08-1.740.009dominant0.04exon 2rs37526611.351.06-1.720.017dominant0.04intron 5rs10495001.381.08-1.750.009dominant0.04exon 12rs8181620.700.52-0.940.019recessive0.303′ flankingrs109296691.251.06-1.480.009dominant0.113′ flankingrs24634630.760.62-0.930.009recessive0.443′ flankingrs24304201.251.08-1.460.004dominant0.323′ flankingrs116949111.341.13-1.590.001dominant0.113′ flankingrs130009160.770.63-0.040.009recessive0.453′ flanking Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2831.
Case 22-2007
Authors: Daniel C. Chung, Sam S. Yoon, Gregory Y. Lauwers, Devanshi Patel
Journal: New England Journal of Medicine (2007)

A 38-year-old woman came to the Gastrointestinal Cancer Genetics Clinic of this hospital because of a family history of breast and gastric cancer. Her mother had died of gastric cancer, and her maternal aunt had bilateral breast cancer and died of gastric cancer. Screening upper gastrointestinal endoscopy had been negative in the patient. A diagnostic procedure was performed.
<i>From the authors</i>
Authors: A. van 't Hul, R. Gosselink
Journal: European Respiratory Journal (2006)

We would like to thank L. Bianchi for his letter to the editors and Ambrosino 1 for his editorial regarding our paper on the effects of training with inspiratory pressure support in patients with chronic obstructive pulmonary disease (COPD) 2. Both reactions focus on the important issue of whether noninvasive ventilatory support (NIVS) during training could now be recommended as an aid in the practical setting of pulmonary rehabilitation.

Is the complex game of assisted ventilation or “mechanical doping” during exercise training in COPD worth the candle? We agree with L. Bianchi that the literature on the effects of training with NIVS in COPD yielded some conflicting results. It must be noted, however, that the study lacking an additional effect of training with NIVS included patients with a relatively mild airway obstruction, well-preserved exercise performance and an …
Abstract 1132: Oncogenic role of EAPII/TTRAP in lung cancer development and its activation of MAPK-ERK pathway
Authors: Chunyang Li, Songqing Fan, Taofeek K. Owonikoko, Fadlo R. Khuri, Shi-yong Sun, Runzhao Li
Journal: Cancer Research (2011)

Abstract Cancer progression involves multiple complex and interdependent steps including progressive proliferation, angiogenesis and metastases. The complexity of these processes requires a comprehensive elucidation of the integrated signaling networks for better understanding. EAPII/TTRAP interacts with multiple cancer-related proteins, but its biological significance in cancer development remains unknown. In this report we identified the elevated level of EAPII/TTRAP protein in non-small cell lung carcinoma (NSCLC) patients and NSCLC cell lines in culture. The oncogenic role of EAPII in lung cancer development was demonstrated using NSCLC cells with genetic manipulations that influence EAPII expression: EAPII overexpression increases proliferation of NSCLC cells with an accelerated transition of cell cycle and facilitates xenograft tumor growth in vivo; EAPII knockdown results in apoptosis of NSCLC cells and reduces xenograft tumor formation. To further explore the mechanism of EAPII's oncogenic role in lung cancer development and to elucidate the potential signaling pathway(s) that EAPII may impact, we employed antibody array to investigate the alternation of the major signaling pathways in NSCLC cells with altered EAPII level. We found that EAPII overexpression significantly activated Raf-1 and ERK1/2, but not JNK and p38 pathways. Consistently, the protein and mRNA levels of MYC and cyclin D1, which are targets of the mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPK-ERK) pathway, are significantly increased by EAPII overexpression. Taken together, we demonstrated that EAPII is an oncogenic factor and the activation of MAPK-ERK signaling pathway by EAPII may contribute to lung cancer development. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1132. doi:10.1158/1538-7445.AM2011-1132